AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14550328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 14550328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (parenting stress and child abuse potential)
Number of subjects: 161
Study 14550328 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's development (mental, motor, and language)
Number of subjects: 161
Study 10382078 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic norgestimate/35 micrograms ethinyl estradiol (NGM/EE)
Number of subjects: 0
Study 10382078 — intervention group
Group type: COMPARATOR
Intervention: Monophasic norethindrone acetate/20 micrograms ethinyl estradiol (NETA/EE)
Number of subjects: 0
Study 10382078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OC
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (day 2)
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch followed by nicotine gum (day 3)
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch followed by nicotine gum and cigarette smoking (day 4)
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicoderm during exercise
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitrol during exercise
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Nicoderm and Habitrol
Number of subjects: 0
Study 9378845 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitrol
Number of subjects: 0
Study 8200309 — intervention group
Group type: EXPERIMENTAL
Intervention: QT dispersion (QTd) in patients with ventricular fibrillation
Number of subjects: 62
Study 8200309 — intervention group
Group type: COMPARATOR
Intervention: QT dispersion (QTd) in patients without ventricular fibrillation
Number of subjects: 62
Study 8200309 — intervention group
Group type: EXPERIMENTAL
Intervention: JT dispersion (JTd) in patients with ventricular fibrillation
Number of subjects: 62
Study 8200309 — intervention group
Group type: COMPARATOR
Intervention: JT dispersion (JTd) in patients without ventricular fibrillation
Number of subjects: 62
Study 3946752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 147
Study 3946752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 147
Study 3946752 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (clindamycin and gentamicin)
Number of subjects: 147
Study 30165984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg)
Number of subjects: 16485
Study 30165984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (25 μg)
Number of subjects: 16485
Study 30165984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluticasone furoate and vilanterol
Number of subjects: 16485
Study 30165984 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 16485
Study 30165984 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of cardiac troponin (≥7.7 ng/l)
Number of subjects: 16485
Study 30165984 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbations
Number of subjects: 16485
Study 28033633 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAS lifting with predominantly oblique-vertical vectors
Number of subjects: 107
Study 28033633 — intervention group
Group type: COMPARATOR
Intervention: SMAS lifting with predominantly oblique-horizontal vectors
Number of subjects: 107
Study 28033633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures placed in specific areas for platysmal plication
Number of subjects: 107
Study 28033633 — intervention group
Group type: COMPARATOR
Intervention: Randomly placed sutures for platysmal plication
Number of subjects: 107
Study 25277740 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 26
Study 25277740 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) in CFS
Number of subjects: 26
Study 25277740 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilt (HUT) in control subjects
Number of subjects: 26
Study 23194213 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-hour day shifts
Number of subjects: 12
Study 20620737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg load, then 90 mg twice daily; n=57)
Number of subjects: 123
Study 20620737 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg load, then 75 mg daily; n=54)
Number of subjects: 123
Study 20620737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 123
Study 19166421 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-containing therapy (lansoprazole 15 mg once-daily, amoxicillin 500 mg twice-daily, metronidazole 250 mg twice-daily)
Number of subjects: 238
Study 19166421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-containing therapy (lansoprazole 15 mg once-daily, amoxicillin 500 mg twice-daily, clarithromycin 250 mg once-daily)
Number of subjects: 238
Study 16041208 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic choledochotomy
Number of subjects: 86
Study 16041208 — intervention group
Group type: COMPARATOR
Intervention: Postoperative ERCP
Number of subjects: 86
Study 11833038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 50 microg/d estradiol for 12 weeks (estrogen replacement therapy [ERT])
Number of subjects: 20
Study 11833038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 50 microg/d estradiol for 12 weeks (ERT)
Number of subjects: 20
Study 11833038 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 10028105 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study 10028105 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0
Study 10028105 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 0
Study 10028105 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic or suppressive treatment
Number of subjects: 0
Study 10028105 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-specific serological tests for HSV antibodies
Number of subjects: 0
Study 7720153 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms.kg‐1 po)
Number of subjects: 80
Study 7720153 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 80
Study 1672878 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (0.5 mg/ml), nasal spray, twice in each nostril, four times a day
Number of subjects: 100
Study 1672878 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (0.5 mg/ml)
Number of subjects: 100
Study 6754384 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 9 mg (Celeston Chronodose)
Number of subjects: 12
Study 6754384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30412233 — intervention group
Group type: EXPERIMENTAL
Intervention: Community of Voices choir intervention
Number of subjects: 390
Study 30412233 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention for 6 months)
Number of subjects: 390
Study 30732169 — intervention group
Group type: EXPERIMENTAL
Intervention: Avaxim
Number of subjects: 108
Study 30732169 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal
Number of subjects: 108
Study 30732169 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix
Number of subjects: 108
Study 28922068 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan-enriched complex (600 mg SDG)
Number of subjects: 0
Study 28922068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26478977 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopenia group (n = 13)
Number of subjects: 24
Study 26478977 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 24
Study 26478977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at baseline and 4 months after surgery
Number of subjects: 24
Study 23340005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose itraconazole (200 mg/day)
Number of subjects: 46
Study 23340005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose itraconazole (600 mg/day)
Number of subjects: 46
Study 21332024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 22
Study 21332024 — intervention group
Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 22
Study 19809292 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver + PEEP
Number of subjects: 30
Study 19809292 — intervention group
Group type: COMPARATOR
Intervention: PEEP alone
Number of subjects: 30
Study 19809292 — intervention group
Group type: COMPARATOR
Intervention: Recruitment maneuver + zero end-expiratory pressure
Number of subjects: 30
Study 19809292 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (induction)
Number of subjects: 30
Study 17348989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day for 12 months
Number of subjects: 34
Study 17348989 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 34
Study 15096079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with 2 mg of risperidone plus 2 mg of lorazepam
Number of subjects: 162
Study 15096079 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular treatment with 5 mg of haloperidol plus 2 mg of lorazepam
Number of subjects: 162
Study 11803349 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 44
Study 11803349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 44
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 2435
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal/Epidural techniques
Number of subjects: 2435
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Anesthesia (GA + S/Ep.)
Number of subjects: 2435
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route for postoperative analgesia (POA)
Number of subjects: 2435
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 2435
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EA)
Number of subjects: 2435
Study 9835726 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics-opioids association (LA + Op) for epidural analgesia
Number of subjects: 2435
Study 8182811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance (n = 655) including physician visits, bone scan, liver echography, chest roentgenography, and laboratory tests at predefined intervals
Number of subjects: 1320
Study 8182811 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (n = 665) with physician visits and only clinically indicated tests
Number of subjects: 1320
Study 8182811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a yearly mammogram
Number of subjects: 1320
Study 2924690 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic combination (hydrochlorothiazide + triamterene)
Number of subjects: 16
Study 2924690 — intervention group
Group type: COMPARATOR
Intervention: Digitalis glycoside
Number of subjects: 16
Study 29630702 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice daily
Number of subjects: 8058
Study 29630702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride, 150 mg twice daily
Number of subjects: 8058
Study 29630702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy, 21‐mg/d patch with tapering
Number of subjects: 8058
Study 29630702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8058
Study 27655905 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (6 courses of modified infusional fluorouracil and folinic acid with oxaliplatin before and after surgery)
Number of subjects: 330
Study 27655905 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (modified infusional fluorouracil and folinic acid with oxaliplatin; 12 cycles)
Number of subjects: 330
Study 25901451 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 250
Study 25901451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 22043026 — intervention group
Group type: EXPERIMENTAL
Intervention: Number Sense Instruction (NSI)
Number of subjects: 101
Study 22043026 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 101
Study 20643454 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-pelvic floor muscle training once a week for 3 months and home exercises
Number of subjects: 73
Study 20643454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback training)
Number of subjects: 73
Study 20643454 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-pelvic floor muscle training
Number of subjects: 73
Study 20643454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 73
Study 18486739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 766
Study 18486739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 766
Study 18486739 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance ustekinumab
Number of subjects: 766
Study 18486739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study 16905398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy with family unit including the patient
Number of subjects: 87
Study 16905398 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy with a group of relatives
Number of subjects: 87
Study 12840177 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated mixed extract (Juice Plus)
Number of subjects: 32
Study 12840177 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 32
Study 10788287 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention administered by nurse and peer advisors
Number of subjects: 0
Study 10788287 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 8706290 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline infusion followed by oral water load (10 ml/kg over 3 minutes)
Number of subjects: 38
Study 1829098 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid suppressive agents (aminoglutethimide, ketoconazole, metyrapone) for 2 months
Number of subjects: 10
Study 1829098 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (discontinuation of other psychotropic drugs)
Number of subjects: 10
Study 7020903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with melphalan, 5-fluorouracil, and methotrexate
Number of subjects: 240
Study 7020903 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy with melphalan followed by 5-fluorouracil and then methotrexate
Number of subjects: 240
Study 31134632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (daily and weekly administration)
Number of subjects: 0
Study 31134632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29166972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (any dose)
Number of subjects: 247
Study 25100233 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood (anxious, sad)
Number of subjects: 0
Study 25100233 — intervention group
Group type: COMPARATOR
Intervention: Positive mood (amused)
Number of subjects: 0
Study 23452658 — intervention group
Group type: EXPERIMENTAL
Intervention: Starplasty tracheotomy
Number of subjects: 65
Study 23452658 — intervention group
Group type: COMPARATOR
Intervention: Traditional tracheotomy (Control Group 1)
Number of subjects: 65
Study 23452658 — intervention group
Group type: COMPARATOR
Intervention: Traditional tracheotomy (Control Group 2)
Number of subjects: 65
Study 22303701 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) administered orally before noise exposure
Number of subjects: 363
Study 22303701 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally before noise exposure
Number of subjects: 363
Study 19640356 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoxypeganine 50 mg (b.i.d. for 3 days)
Number of subjects: 18
Study 19640356 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoxypeganine 100 mg (b.i.d. for 3 days)
Number of subjects: 18
Study 19640356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17676355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 20
Study 17676355 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-treatment results)
Number of subjects: 20
Study 15626322 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional reasoning
Number of subjects: 508
Study 15626322 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based reasoning
Number of subjects: 508
Study 15626322 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of anxiety and depression
Number of subjects: 508
Study 11344201 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg/week, im)
Number of subjects: 54
Study 11344201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11344201 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (3 times/week)
Number of subjects: 54
Study 11344201 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 54
Study 11344201 — intervention group
Group type: COMPARATOR
Intervention: Men with AIDS wasting
Number of subjects: 54
Study 11344201 — intervention group
Group type: COMPARATOR
Intervention: Controls (35 age-matched healthy non-HIV-infected subjects)
Number of subjects: 54
Study 9671187 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drain
Number of subjects: 202
Study 9671187 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 202
Study 8013019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine echocardiography (5-10 mcg/kg/min over 5 min)
Number of subjects: 47
Study 8013019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dobutamine echocardiography (20-40 mcg/kg/min over 3 min)
Number of subjects: 47
Study 8013019 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole echocardiography (0.56 mg/kg over 4 min + 0.28 mg/kg over 2 min)
Number of subjects: 47
Study 8013019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 47
Study 8013019 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole echocardiography
Number of subjects: 47
Study 8013019 — intervention group
Group type: EXPERIMENTAL
Intervention: Late spontaneous functional recovery
Number of subjects: 47
Study 2583149 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of caffeine per kg of body-weight in 200 ml of orange juice (CA)
Number of subjects: 5
Study 2583149 — intervention group
Group type: COMPARATOR
Intervention: 200 ml of orange juice (C)
Number of subjects: 5
Study 133601 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial dosage of 2,500 mg aurothioglucose in 21 weeks, followed by maintenance dosage
Number of subjects: 196
Study 133601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of 1,000 mg gold in 21 weeks, followed by maintenance dosage
Number of subjects: 196
Study 133601 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections after high dosage
Number of subjects: 196
Study 133601 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections after low dosage
Number of subjects: 196
Study 29065052 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg) and Taurine (1 g)
Number of subjects: 11
Study 29065052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin ∼1 g)
Number of subjects: 11
Study 31634648 — intervention group
Group type: EXPERIMENTAL
Intervention: ED (75 mg/m2 of epirubicin and 75 mg/m2 of docetaxel)
Number of subjects: 3010
Study 31634648 — intervention group
Group type: COMPARATOR
Intervention: FEC (500 mg/m2 of fluorouracil, 100 mg/m2 of epirubicin and 500 mg/m2 of cyclophosphamide)
Number of subjects: 3010
Study 31634648 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 3010
Study 28573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based skills training intervention
Number of subjects: 285
Study 28573704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 25813214 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2250
Study 25813214 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2250
Study 25813214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2250
Study 23722666 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 200
Study 23722666 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (conventional method of in-person evaluations)
Number of subjects: 200
Study 21742425 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher financial autonomy
Number of subjects: 600
Study 21742425 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher participation in decision-making
Number of subjects: 600
Study 19343970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (0.50 mg + 1.25 mg per kg body weight three times daily after meals)
Number of subjects: 30
Study 19343970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19343970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa
Number of subjects: 30
Study 17329508 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of micronized 17beta‐estradiol (n=96)
Number of subjects: 218
Study 17329508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=122)
Number of subjects: 218